Skip Navigation



Europace Advance Access published online on October 3, 2009
Europace, doi:10.1093/europace/eup300
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Guglin, M.
Right arrow Articles by Curtis, A. B.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Guglin, M.
Right arrow Articles by Curtis, A. B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org

REVIEW

Introducing a new entity: chemotherapy-induced arrhythmia

Maya Guglin*, Mohsen Aljayeh, Saleemuddin Saiyad, Rias Ali and Anne B. Curtis

Department of Cardiology, University of South Florida, 2A Columbia Drive, Suite 5074, Tampa, FL 33618, USA

The relationship between chemotherapy and arrhythmias has not been well established. We reviewed the existing literature to better understand this connection. We reviewed published reports on chemotherapy-induced arrhythmias in English using the PubMed/Medline and OVID databases from 1950 onwards as well as lateral references. Arrhythmias were reported as a side effect of many chemotherapeutic drugs. Anthracyclines are associated with atrial fibrillation (AF) at a rate of 2–10%, but rarely with ventricular tachycardia (VT)/fibrillation. Taxol and other antimicrotubular drugs are safe in terms of pro-arrhythmic side effects and do not cause any consistent rhythm abnormalities. Arrhythmias induced by 5-fluorouracil, including VT, are mostly ischaemic in origin and usually occur in the context of coronary spasm produced by this drug. Cisplatin—particularly with intrapericardial use—is associated with a very high rate of AF (12–32%). Melphalan is associated with AF in 7–12% of cases, but it does not appear to cause VT. Interleukin-2 is linked to frequent arrhythmia, mostly AF. We summarized the available data on chemotherapy-induced arrhythmia, particularly AF and VT. Studies with prospective data collection and thorough analyses are needed to establish a causal relationship between certain anticancer drugs and arrhythmia.

Key Words: Chemotherapy, Arrhythmia, Atrial fibrillation, Ventricular tachycardia

* Corresponding author. Tel: +1 813 259 0992, Email: mguglin{at}gmail.com; mguglin{at}health.usf.edu

Manuscript submitted 3 August 2009. Accepted after revision 9 September 2009.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.